Sanofi Invests $180 Mln Equity In AI Startup Owkin To Develop Oncology Pipeline

French drug major Sanofi (SNYNF,SNY) announced Thursday an equity investment of $180 million and a new strategic collaboration with Owkin, a French American startup that specializes in artificial intelligence or AI and federated learning for medical research.

With the collaboration, the company aims to advance its oncology pipeline in core areas such as lung cancer, breast cancer and multiple myeloma. The deal comprises discovery and development programmes in four exclusive types of cancer.

The total payment would be $90 million for three years plus additional research milestone-based payments.

The collaboration agreement will allow Sanofi to work closely with Owkin in identifying new oncology treatments across four cancers.

Sanofi will leverage the comprehensive Owkin Platform, in order to find new biomarkers and therapeutic targets, building prognostic models, and predicting response to treatment from multimodal patient data.

The company said its investment will support Owkin's development and goal to grow the world's leading histology and genomic cancer database from top oncology centers.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Twitter Inc. said it is expanding engineering center in Singapore, its Asia Pacific headquarters. The number of engineers there will be doubled to over 100 staff in 2023. Focused on product innovations and improvements, the new hires will work from Singapore on global initiatives for Twitter. These new technical hires will span roles in engineering, data science, machine learning and product... The U.S. Food and Drug Administration (FDA) has granted approval and reissued the revised Emergency Use Authorization (EUA) to Gilead Sciences Inc. for antiviral drug Veklury (remdesivir) to treat certain non-hospitalized adults and pediatric patients with mild-to-moderate COVID-19 disease. Shares of Philips Electronics NV were losing more than 4 percent in the morning trading in Amsterdam as well as in pre- market activity on the NYSE, after the Dutch consumer electronics giant reported lower profit and sales in its fourth quarter. Comparable sales declined, while comparable order intake increased. Further, the company maintained its dividend, and said it expects to start the year
Follow RTT